PCOS (polycystic ovary syndrome) is a hormonal endocrine disorder affecting child bearing age women, i.e. women from 15 to 49 years of age. Owing to increasing number of patients affected by PCOS, the global PCOS drugs market is on a robust growth. In terms of revenue, global market for polycystic ovary syndrome drugs is expected to reach US $1,154.8 million until 2024. And it is estimated to grow at 4.6% CAGR over the forecast period, 2016 to 2024, as per the report by Persistence Market research.
APAC to Witness a Robust Growth in Market Revenue at 5.5% CAGR
Global PCOS drugs market is widespread across five major regions viz. Latin America, Asia Pacific (APAC), Europe, Middle East & Africa (MEA), and North America. Europe and North America are expected to dominate the global PCOS drugs market. Collectively, they were estimated to account for around 57% share of market value by 2016 end. Asia Pacific and Latin America are emerging to be the fastest growing markets, over the forecast period. The market revenue from APAC is estimated to witness a robust increase at 5.5% CAGR, over the forecast period.
Hospital Pharmacies Segment Estimated to Reach 49.8% Market Share by 2024
Based on distribution channels, the market is categorised into drug stores/OTC, fertility clinics, hospital pharmacies and E-commerce. 48.3% market share was expected to be accounted by hospital pharmacies segment in 2016 and estimated to increase by 2024 reaching 49.8%. This segment is considered to be lucrative in terms of revenue growth. The E-commerce segment is anticipated to grow at 4.3% CAGR over the forecast period, which was expected to be valued at US $118.8 million in the previous year.
Oral Contraceptives Segment Expected to be Lucrative by 2024 End
On the basis of drug class, the market is classified as anti-depressants, decarboxylase inhibitors, Diuretics, insulin sensitising agents, aromatase inhibitors, ornithine and, oral contraceptives. The contraceptive segment is estimated to exhibit 1.6X revenue growth by 2024 end. This segment is estimated to reflect 5.4% CAGR during the forecast period, to reach US $355.7 million in terms of market value by 2024 end. 4.8% CAGR is expected to be witnessed by insulin sensitising agent over the forecast period. The market value of anti-depressants was expected to reach US $51.1 million with a growth rate of 4.3% CAGR.
Need for Effective Associated Disease Management is Fuelling the PCOS Drugs Demand
PCOS generally results into obesity, hirsutism and infertility. This has necessitated effective associated diseases management which in turn is fuelling demand for PCOS drugs. Increasing awareness among the patients and increasing prevalence of PCOS is driving the growth of global PCOS drugs market. In addition, the revenue growth of PCOS drugs market is driven by significant adoption of increasing prevalence of combination drugs by patient population in the near future. In contrast, increasing generics-associated side effects and absence of FDA approved drugs are the factors restraining the global market growth of PCOS drugs.
Request and Download Sample Report@ https://www.persistencemarketresearch.com/samples/3682